Comparison of Lu-177 obtained from two different commercial vendors for peptide receptor radionuclide therapy of neuroendocrine tumor patients: Preliminary results

被引：0
|
作者：
Lehmann, C. [1 ]
Prasad, V. [1 ]
Schuchardt, C. [1 ]
Mueller, D. [1 ]
Zachert, C. [1 ]
Baum, R. P. [1 ]
机构：
[1] Zentralklin Bad Berka, Ctr PET CT, Clin Nucl Med, Bad Berka, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2010年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S440 / S440
页数：1
相关论文
共 50 条
  • [41] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study
    Michela Del Prete
    François-Alexandre Buteau
    Jean-Mathieu Beauregard
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1490 - 1500
  • [42] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
    Michela Del Prete
    François-Alexandre Buteau
    Frédéric Arsenault
    Nassim Saighi
    Louis-Olivier Bouchard
    Alexis Beaulieu
    Jean-Mathieu Beauregard
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 728 - 742
  • [43] Preliminary dosimetric study with 177-Lutetium Peptide Receptor Radionuclide Therapy for Pediatric Patients with neuroendocrine tumors
    Cassano, B.
    Genovese, E.
    Polito, C.
    Longo, M.
    Donatiello, S.
    Napolitano, A.
    Insero, T.
    Valeri, S.
    Pizzoferro, M.
    Serra, A.
    Garganese, M. C.
    Cannata, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S87 - S87
  • [44] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
    Del Prete, Michela
    Buteau, Francois-Alexandre
    Arsenault, Frederic
    Saighi, Nassim
    Bouchard, Louis-Olivier
    Beaulieu, Alexis
    Beauregard, Jean-Mathieu
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (03) : 728 - 742
  • [45] Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment
    Hamiditabar, Mohammadali
    Ali, Muzammil
    Roys, Joseph
    Wolin, Edward M.
    O'Dorisio, Thomas M.
    Ranganathan, David
    Tworowska, Izabela
    Strosberg, Jonathan R.
    Delpassand, Ebrahim S.
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (06) : 436 - 443
  • [46] Peptide Receptor Radionuclide Therapy using SSTR antagonists: biokinetics and dosimetry of Lu-177 DOTA-LM3
    Schuchardt, C.
    Wiessalla, S.
    Singh, A.
    Zhang, J.
    Kulkarni, H. R.
    Mueller, D.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S90 - S90
  • [47] Evaluation of Kidney Dose in Neuroendocrine Tumors Patients after Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE
    Hidayati, N. R.
    Poon, A.
    Willowson, K.
    Eslick, E.
    Ryu, H.
    Bailey, D. L.
    ATOM INDONESIA, 2019, 45 (03) : 147 - 152
  • [48] Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE
    Pretot, Dominique
    Engel-Bicik, Ivette
    Kenkel, David
    Kaufmann, Philipp A.
    Treyer, Valerie
    Siebenhuner, Alexander R.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (03) : 1204 - 1217
  • [49] Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors
    Jiang, Yuanyuan
    Liu, Qingxing
    Wang, Guochang
    Sui, Huimin
    Wang, Rongxi
    Wang, Jiarou
    Zhang, Jingjing
    Zhu, Zhaohui
    Chen, Xiaoyuan
    THERANOSTICS, 2022, 12 (15): : 6437 - 6445
  • [50] Patients with Advanced Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy with 177Lu-DOTATE: Data from Spanish SEPTRALU Registry
    Mitjavila, M.
    Percovich, J. C.
    Pombo Pasin, M. C.
    Bello, P.
    Arbizu, J.
    Llana, B.
    Riesco, M. C.
    Muros, M. A.
    Estenoz, J.
    Rotger, A.
    Aller, J.
    Jimenez-Fonseca, P.
    NEUROENDOCRINOLOGY, 2019, 108 : 223 - 223
12345